NuVasive (NUVA) announced that proxy advisory firm, Glass Lewis & Co., recommends that NuVasive shareholders vote "FOR" the shareholder proposal to adopt the merger agreement with Globus Medical (GMED) at NuVasive’s upcoming special meeting of shareholders scheduled for April 27, 2023. Only holders of record of NuVasive common stock as of the close of business on March 24, 2023, are entitled to vote at the special meeting. Glass Lewis is the second independent proxy advisory firm to recommend that NuVasive shareholders vote "FOR" the Globus Medical merger proposal. As previously announced on April 14, 2023, Institutional Shareholder Services also recommended that NuVasive shareholders vote "FOR" the merger proposal. The NuVasive Board of Directors strongly urges NuVasive shareholders to vote "FOR" all the NuVasive proposals set forth in the definitive proxy statement for the NuVasive special meeting, including "FOR" the proposal to adopt the merger agreement with Globus Medical. The merger of NuVasive and Globus Medical is expected to close in the middle of 2023, subject to the approval of both companies’ shareholders, regulatory approval, and other customer closing conditions.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NUVA:
- Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending NuVasive Shareholders Vote “FOR” the Proposed Merger with Globus Medical
- TD Cowen medical devices analyst to hold analyst/industry conference call
- Leading Independent Proxy Advisory Firm ISS Recommends NuVasive Shareholders Vote “FOR” the Proposed Merger with Globus Medical
- NuVasive says ISS recommends vote in favor of Globus deal
- NuVasive, Globus Medical continue to expect transaction to close mid-2023
